China NMPA grants marketing authorization to IMPACT Therapeutics’ Senaparib for 1L maintenance therapy in ovarian cancer: Shanghai Saturday, January 18, 2025, 15:30 Hrs [IST] IM ...

These cancer cells have switched to this backup system to repair DNA damage and by turning it off, PARP inhibitors cause them to die from a process known as “synthetic lethality” as mutations ...

HRD+ cancers, including BRCA1/2 mutations ... Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.

HRD+ cancers, including BRCA1/2 mutations, represent up to 50% of ovarian cancers ... Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality ...